QPPV Nomination in Kenya: The Complete PPB Guide

What is a QPPV?

A Qualified Person for Pharmacovigilance is a qualified pharmacist who holds personal accountability for the establishment and maintenance of a company's pharmacovigilance (PV) system. The concept originated in European Medicines Agency (EMA) regulation and has been adopted - with local variations - by most stringent regulators worldwide.

In Kenya, the Pharmacy and Poisons Board (PPB) requires every Marketing Authorisation Holder (MAH) of a registered pharmaceutical product to nominate a QPPV. The QPPV is the named individual who answers to PPB for everything related to that company's safety reporting, adverse event monitoring, and periodic safety reviews.

Why PPB requires a local QPPV

Pharmacovigilance is built on timely reporting. A serious adverse drug reaction detected in Mombasa on a Monday evening needs to reach the PPB's Pharmacovigilance Electronic Reporting System (PvERS) within 15 calendar days - and often faster. That is impossible if the designated safety contact is in another time zone, works for a different entity, or has no accountability to the local regulator.

PPB's position is simple: local accountability requires local presence. The regulator must be able to call a specific, named, Kenyan-licensed pharmacist and get immediate, substantive answers. Hence the requirement.

This is in addition to any global Qualified Person you may already have. Multinational MAHs typically keep their EU-QPPV for global safety oversight and appoint a Kenyan QPPV for local duties. The two work together; they do not replace each other.

Who qualifies as a QPPV in Kenya?

PPB's QPPV must meet all of the following:

• Be a registered pharmacist in Kenya - a valid practising certificate from the Pharmacy and Poisons Board is non-negotiable.
• Be physically based in Kenya - a permanent resident with a Kenyan address reachable during normal business hours.
• Have demonstrable pharmacovigilance training and experience - formal PV training from a recognised body (e.g., UMC Uppsala, WHO, an accredited university course) plus ideally 2+ years of practical PV experience.
• Be reachable 24/7 for urgent safety matters - PPB expects a documented emergency contact procedure. In practice this means a dedicated phone and email monitored around the clock.
• Be formally nominated on the company's Marketing Authorisation file - a signed letter of appointment from the MAH's senior executive, accepted by the QPPV, and filed with PPB.

A common misconception: the QPPV does not need to be a full-time employee of the MAH. They can be a contracted specialist under an external service arrangement - as long as the accountability, reachability, and qualifications are clearly documented.

Core QPPV responsibilities

A QPPV's day-to-day accountability covers:

• ICSR intake and assessment: receiving Individual Case Safety Reports from healthcare professionals, patients, literature, regulators, and the MAH's own affiliates. Each case is triaged for seriousness, assessed for causality, medically reviewed, and submitted to PvERS within the applicable deadline (15 calendar days for serious; 90 for non-serious).
• Signal detection: running periodic signal reviews across the case database to identify new safety signals. These are graded, investigated, and either closed or escalated to a Risk Management Plan action.
• PSUR / PBRER authoring: preparing Periodic Safety Update Reports per ICH E2C(R2) at the frequency stipulated in each product's conditions of approval - typically 6-monthly for the first 2 years, annually through year 5, then 3-yearly. Use our free PSUR checklist tool to track every required section.
• Risk Management Plans (RMPs): drafting product-specific RMPs and keeping them current as new safety information emerges.
• Literature monitoring: weekly search of PubMed, Embase, and local medical literature for safety-relevant publications on the MAH's products.
• Regulator correspondence: primary point of contact for PPB on safety matters; representing the MAH at PV audits and inspections.
• PV System Master File (PSMF) maintenance: keeping the PSMF - the documented description of the MAH's PV system - current and available to PPB on request.
• Staff training: ensuring the MAH's commercial, medical, and customer-facing teams know how to recognise and escalate potential adverse events.

The nomination process, step by step

1. Identify your candidate. They must meet every qualification above. If you don't have an in-house candidate with these exact credentials, engage an external QPPV service (see below).
2. Draft the letter of appointment. This is a formal letter from the MAH's senior executive (CEO, MD, or Country Head), addressed to the nominated QPPV, stating the scope of their appointment, the list of products covered, and the authority to make safety decisions on the MAH's behalf.
3. Get the QPPV's signed acceptance. The QPPV countersigns the appointment letter, confirming they understand and accept the scope.
4. Assemble the dossier. PPB typically expects: the signed appointment letter, the QPPV's current Kenya-registered pharmacist certificate, a brief CV highlighting PV training and experience, and evidence of 24/7 reachability (dedicated number + email).
5. Update the PV System Master File. If you already have a PSMF on file with PPB, the new QPPV details must be reflected there. If this is your first PV system, you'll need to draft a PSMF.
6. Notify PPB. Submit the nomination package to PPB's Pharmacovigilance Department. There is a formal acknowledgement process; retain the reference number.
7. Register the QPPV in PvERS. Set up or update the PvERS account so ICSRs can be submitted under the new QPPV's credentials.
8. Inform the field. Tell your medical and commercial teams, your distributors, and any partner organisations who the new QPPV is and how to reach them.

In-house vs. outsourced QPPV

Both models are PPB-compliant. The right choice depends on portfolio size and operating model.

Go in-house if: you have a portfolio of 10+ active products, a reasonably steady flow of ICSRs, and a pharmacist on staff with formal PV training. A full-time QPPV typically costs KES 3-5 million per year in Kenya plus overheads. At scale, that's cheaper than outsourcing.

Go outsourced if: you're an MAH with 1-10 products, a parent entity overseas, or a distributor taking on its first PPB PV obligations. An outsourced QPPV service from a specialist like The Pharma Partner starts from KES 40,000 per month (see full PV pricing). You get a PPB-registered QPPV, 24/7 ADR intake, PvERS submission, signal detection, and audit representation - without the fixed overhead.

A third option: start outsourced, convert to in-house once you hit scale. Our retainer contracts are deliberately structured to allow clean handover to an in-house hire when you're ready.

Common mistakes to avoid

• Nominating your global QPPV as the Kenya QPPV. PPB will reject. You need a Kenya-registered pharmacist.
• Appointing the Responsible Pharmacist as QPPV by default. The "Responsible Pharmacist" under PPB rules oversees the physical premises. The QPPV oversees a different function. Same person can hold both roles, but only if they genuinely have PV qualifications.
• No documented 24/7 coverage. If PPB or a healthcare professional can't reach the QPPV after 5pm, the nomination is on paper only. Document backup contacts.
• No PSMF. A QPPV without a documented PV system is exposed at the first inspection. Our SOP development service includes PV SOPs and a PSMF template.
• Missing literature monitoring. Failing to perform and document weekly literature searches is one of the top PV audit findings globally. Build it into your QPPV workflow from day one.
• Treating PSURs as optional. They're not. Missed PSURs cause renewal rejections.
• Assuming the distributor handles PV. PV accountability sits with the MAH, not the distributor. If you import under your own registration, the obligation is yours.

Cost and timeline

For a typical MAH with 3-10 registered products, setting up a compliant QPPV arrangement from scratch takes:

• Week 1-2: QPPV identification and appointment letter drafting.
• Week 3-6: PSMF drafting, SOP development, staff training.
• Week 7-8: PPB submission and PvERS account setup.
• Week 9+: BAU - ongoing ICSR processing, monthly signal reviews, quarterly PSURs as applicable.

Our published PV pricing covers each tier: PV system setup (KES 180K-350K), QPPV retainer (from KES 40K/month), PSUR/PBRER preparation (KES 80K-200K per report), and ad-hoc ICSR processing (KES 5K-12K per case).

Next steps

If you're an MAH without a PPB-compliant QPPV arrangement, the regulatory exposure grows every month. Start with a 30-minute strategy call:

Related resources

• Pharmacovigilance category overview - all our PV services and tools in one place
• Pharmacovigilance services - QPPV nomination, PV system setup, PSURs
• Free ADR Report Generator - CIOMS-style form for PvERS submission
• Free PSUR / PBRER checklist - track every ICH E2C(R2) section
• Pharmacovigilance pricing - transparent fees for every tier